EDGAR·FLOW

Alector, Inc. — Form 8-K

Filed October 5, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 78/100
What the filing says
Alector granted Genentech exclusive global rights to develop and commercialize AL050, a brain-penetrant GCase enzyme replacement therapy for Parkinson's disease and neurodegeneration, using Alector's proprietary ABC blood-brain barrier delivery platform. Alector receives $100 million upfront payment, up to $1.17 billion in milestone payments (development, regulatory, commercial), and tiered royalties on net sales. Genentech assumes all development, regulatory, manufacturing, and commercialization responsibility; Alector retains ABC platform ownership and rights to its wholly owned pipeline (AL137, AL164, AL062), with cash runway extended to 2029.
Why this rating

Major deal—$100M upfront ≈87% of company market cap; $1.17B milestones + royalties provides material validation and financial runway. Business-transformative for Alector's scale; validates platform, funds pipeline, reduces cash burn risk.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$2.46
+10 min · unknown
$2.31 ▼ 5.86%
+30 min · unknown
$2.21 ▼ 10.13%
+1 hr · unknown
$2.28 ▼ 7.24%
+4 hrs · unknown
$2.20 ▼ 10.53%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ ALEC · stock on Yahoo Finance ↗

See more from October 5, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.